Please login to the form below

Vimpat

This page shows the latest Vimpat news and features for those working in and with pharma, biotech and healthcare.

UCB bags FDA approval for epilepsy drug Briviact

Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets. ... Vimpat added another 495m.

Latest news

UCB wins European approval for epilepsy drug Briviact

The drug adds to an epilepsy treatment portfolio at UCB currently represented by Vimpat (lacosamide) - with sales of 495m in the first nine months of 2015 - along with Keppra (levetiracetam) which
UCB boosted by core medicines growth

Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome ... Sales of Vimpat increased by 15%
UCB submits brivaracetam for use in epilepsy

The company has since turned to other drugs in its epilepsy portfolio, including Vimpat (lacosamide). ... At the end of last year UCB announced a partnership with Daiichi Sankyo to bring Vimpat to Japan.
New UCB CEO Jean-Christophe Tellier expands his executive team

Hands new roles to Emmanuel Caeymaex, Bharat Tewarie and Jeff Wren
UCB partners with Daiichi to bring epilepsy drug to Japan

Companies partner on expanding market for Vimpat. UCB has teamed up with Daiichi Sankyo to commercialise its epilepsy treatment lacosamide in Daiichi's home nation of Japan. ... Vimpat is an important drug for UCB as it looks to overcome the loss in

More from news
Approximately 7 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Pharma deals during November 2013

Certainly the good performances from key products such as Cimzia, Vimpat and Neupro may well appeal to those companies feeling a little pipeline bereft.
VIDEO interview: Neil Weir, UCB

For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for ... As for the future of the company,
Interview with Roch Doliveux, UCB

It is the same with Vimpat. Peak sales were once 350m; now, estimates are at least 1.2bn. ... Vimpat treats a subset of epilepsy, partial onset seizures. One in three patients has this refractory type of seizure.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Account Director, Healthcare Marketing Agency: Salary TBC

Project Manager/ Account Manager: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Digital Account Director: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Manager, MedicalCommunications/ Healthcare PR: benefits

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account Director, Medical Education: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Medical Writer: Great salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...